Advertisement
Advertisement

ITCI

ITCI logo

Intra-Cellular Therapies Inc

83.47
USD
-0.67
-0.80%
Dec 20, 15:59 UTC -5
Closed
...

Intra-Cellular Therapies Inc Profile

About

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.

Info & Links

CEO

Sharon Mates

Headquarters

430 EAST 29TH STREET
NEW YORK, NY 10016, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

73

Employees

610

Intra-Cellular Therapies Inc Statistics

Valuation Measures

Market Capitalization2

8.85B

Enterprise Value

8.38B

Enterprise Value/EBITDA(ttm)

-64.65

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

14.53

Price to Book(mrq)

7.79

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

92.33%

Operating Margin(ttm)

-14.07%

Profit Margin(ttm)

-14.30%

Return on Equity(ttm)

-9.93%

Return on Invested Capital(ttm)

-11.09%

Return on Assets(ttm)

-8.38%

Income Statement

Revenue(ttm)

613.73M

Revenue Per Share(ttm)

5.79

Gross Profit(ttm)

566.47M

EBITDA(ttm)3

-129.67M

Net Income Available to Common(ttm)

-86.37M

Diluted EPS(ttm)

-0.87

Share Statistics

Beta (5Y Monthly)

0.95

52-Week Change

35.81%

S&P 500 52-Week Change

24.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

106.02M

Dividend Yield

0.00%

Float4

103.26M

% Held by Insiders

2.60%

% Held by Institutions

92.33%

Balance Sheet

Total Cash(mrq)

1.01B

Total Cash Per Share(mrq)

9.51

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

7.66%

Quick Ratio(mrq)

7.51%

Book Value Per Share(mrq)

10.80

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.57

Free Cash Flow(ytd)

-60.85M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement